{"id":"NCT00458393","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","briefTitle":"Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men","officialTitle":"Chemoprophylaxis for HIV Prevention in Men","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2014-02","completion":"2014-02","firstPosted":"2007-04-10","resultsPosted":"2018-01-24","lastUpdate":"2021-11-02"},"enrollment":2499,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["HIV Infections"],"interventions":[{"type":"DRUG","name":"daily TDF/FTC","otherNames":["truvada"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"TDF/FTC","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether daily use of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) can prevent HIV infection in men who also receive HIV counseling, condoms, and treatment for other sexually transmitted infections (STIs).","primaryOutcome":{"measure":"HIV Seroconversion","timeFrame":"Monthly follow-up through a median of 1.2 years","effectByArm":[{"arm":"TDF/FTC","deltaMin":48,"sd":null},{"arm":"Placebo","deltaMin":83,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.002"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":true,"inclusionCount":9,"exclusionCount":10},"locations":{"siteCount":11,"countries":["United States","Brazil","Ecuador","Peru","South Africa","Thailand"]},"refs":{"pmids":["21091279","37969014","31192894","29415175","28639995","27658870","27572401","26797207","25908682","25230290","24740633","24613084","23435697"],"seeAlso":["http://www.nejm.org/doi/full/10.1056/NEJMoa1011205"]},"adverseEventsSummary":{"seriousAny":{"events":92,"n":1226},"commonTop":["PHARYNGITIS","PARASITIC INFECTION INTESTINAL","ALANINE AMINOTRANSFERASE INCREASED","BILIRUBIN INCREASE","DIARRHOEA"]}}